Abstracts tagged "outcomes and prednisolone"

Abstract Number: 2157 • 2015 ACR/ARHP Annual Meeting
Relapse Characteristics and Glucocorticoid Use in Patients with Biopsy-Proven Giant Cell Arteritis
Matthew J. Koster¹, Cristian Labarca², Cynthia S. Crowson³, Ashima Makol¹, Steven R. Ytterberg⁴, Eric L. Matteson¹ and Kenneth J. Warrington¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Clinica Alemana Universidad del Desarrollo, Santiago, Chile, ³Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Rheumatology Division, Mayo Clinic, Rochester, MN
Background/Purpose: Relapses in patients with giant cell arteritis (GCA) are common and often lead to higher cumulative use of glucocorticoids. This study aims to evaluate…
Abstract Number: 798 • 2014 ACR/ARHP Annual Meeting
Frequency and Predictive Variables of Relapses in Patients with Biopsy-Proven Giant Cell Arteritis
Luigi Boiardi¹, Giovanna Restuccia², Francesco Muratore¹, Alberto Cavazza³, Luca Cimino⁴, Raffaella Aldigeri⁵, Pierluigi Macchioni¹, Maria Grazia Catanoso⁶, Nicolò Pipitone¹ and Carlo Salvarani¹, ¹Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ²Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ³Pathology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ⁴Ophthalmology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ⁵Clinical and experimental Medicine, Università di parma, Parma, Italy, ⁶Rheumatology Service, Arcispedale S Maria Nuova, Reggio Emilia, Italy
Background/Purpose: Giant cell arteritis (GCA) is a vasculitis that involves large and medium sized arteries in patients older than 50 years. Relapses and recurrences of…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.